Showing 2551-2560 of 3039 results for "".
- Oxurion NV to Focus Resources on Clinical Assets THR-687 and THR-149https://modernod.com/news/oxurion-nv-to-focus-resources-on-clinical-assets-thr-687-and-thr-149/2479325/Oxurion announced a restructuring plan aimed at better aligning resources towards executing its clinical development strategy, including advancing its two novel programs, THR-687 and THR-149, according to a company news release. Following a detailed review of its operations and gr
- Nicox’s Licensee Bausch + Lomb Receives Approval for Vyzulta in the United Arab Emirateshttps://modernod.com/news/nicoxs-licensee-bausch-lomb-receives-approval-for-vyzulta-in-the-united-arab-emirates/2479326/Nicox announced that its exclusive global licensee Bausch + Lomb has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in the United Arab Emirates. Now approved in 12 countries
- CooperVision Announces Uniform Markings Across Blanchard Onefit Family of Scleral Lenseshttps://modernod.com/news/coopervision-announces-uniform-markings-across-blanchard-onefit-family-of-scleral-lenses/2479312/CooperVision Specialty EyeCare announced that lens markings are now uniform across the entire Blanchard Onefit family of scleral lenses, including Onefit MED and Onefit MED+. The uniform markings for front torics and toric haptics across the Onefit family aid in distinguishing whether quadrant sp
- Tarsus Announces Positive Results of Saturn-1 Trial Evaluating TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-saturn-1-trial-evaluating-tp-03-for-the-treatment-of-demodex-blepharitis/2479309/Tarsus Pharmaceuticals announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis. Results demons
- Zubisoft Launches New IOL Treatment Plannerhttps://modernod.com/news/zubisoft-launches-new-iol-treatment-planner/2479307/Switzerland-based Zubisoft and IBRA have released a new IOL treatment planner, which is now a part of IBRA Cataract Services. In addition to higher visual acuity, the new planner allows surgeons to achieve more accurate results. The lower rate of necessary retreatments results in cost savings for
- US to Buy 500 Million Doses of Pfizer, BioNTech COVID-19 Vaccine for Donation to Poorest Nationshttps://modernod.com/news/us-to-buy-500-million-doses-of-pfizer-biontech-covid-19-vaccine-for-donation-to-poorest-nations/2479284/Pfizer and BioNTech said Thursday that they will provide 500 million doses of the COVID-19 vaccine BNT162b2 to the US government at a not-for-profit price to support immunization programs in low- and lower-middle-income countries, according to FirstWord. The companies noted that 200 million doses
- Johnson & Johnson Vision Expands “Sight For Kids” Program and Unveils “Vision for Good” Community Impact Reporthttps://modernod.com/news/johnson-johnson-vision-expands-sight-for-kids-program-and-unveils-vision-for-good-community-impact-report/2479256/Johnson & Johnson Vision announced the expansion of nonprofit program
- Vyluma Launches With Myopia Treatment In Phase 3 Developmenthttps://modernod.com/news/vyluma-inc-launches-with-robust-opthalmic-portfolio-leading-with-a-pharmaceutical-treatment-in-phase-iii-for-myopia/2479239/Vyluma announced its establishment as a wholly-owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eye drop to slow the progression of myopia in children. NVK002 is currently in late phase 3
- Alcon Data Highlights Benefits of Specific AcrySof Modelshttps://modernod.com/news/alcon-data-highlights-benefits-of-specific-acrysof-models/2479232/Alcon has announced the publication of the National Ophthalmology Database (NOD) audit by The Royal College of Ophthalmologists (RCOphth), which collects data on cataract surgery performed in England, Wales and Guerns
- Heine OMEGA 600 Indirect Ophthalmoscope Launched In the UKhttps://modernod.com/news/heine-omega-600-indirect-ophthalmoscope-launched-in-the-uk/2479195/John Weiss & Son has announced the launch of the Heine Omega 600 Indirect Ophthalmoscope in the UK. The new OMEGA 600 enables the clinician to provide a more accurate diagnosis. It features superior non-reflective glass optics, sharp images and reliable, natural colors. Stereoscopic ad